TAVI: dónde estamos y a dónde vamos


Daniel Berrocal
2014-12-05

MD, PhD, MTSAC, FACC
Jefe de Cardiología Intervencionista 
Hospital Italiano – Buenos Aires

More articles by this author

Scaffold bioabsorbibles. Estado Actual y Proyección

Roberto Botelho2014-12-05MD, PhD

Estado Actual del Cierre Percutáneo de la Orejuela Auricular Izquierda

Aníbal Damonte 2014-12-05Departamento de Cardiología IntervencionistaInstituto Cardiovascular de RosarioRosario, Argentina

Revascularización Percutánea Coronaria Aplicación de los Ultimos Avances en Latinoamérica

Hugo Londero2014-12-05Sanatorio Allende – CórdobaAgentina 

Angioplastia de Tronco Coronário Izquierdo: Perspectiva

Gilberto L. Nunes2014-12-05Hospital Divina Providencia. Porto Alegre, RSBRASIL  

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...